A combination treatment for acute myocardial infarction
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- ORION CORPORATION
- Publication Date
- 2005-06-08
- Estimated Expiration
- Not applicable · inactive patent
Smart Images
Figure 1
Abstract
Description
technical field
[0001] The present invention relates to a method for treating myocardial infarction, that is, co-administering a thrombolytic agent and levosimendan or a pharmaceutically acceptable salt thereof to a patient in need of treatment. The present invention also relates to a pharmaceutical product comprising a thrombolytic agent and levosimendan or a pharmaceutically acceptable salt thereof as a combined preparation. Background of the invention
[0002] Myocardial infarction is an important complication characterized by coronary artery disease, usually caused by a sharp drop in coronary blood flow resulting in thrombosis. Thrombolytic therapy, applied intravenously, is widely used, which prevents the reflow of blood to the blocked coronary artery and stores it. Thrombolytics are drugs used to dissolve fibrin-platelet-like thrombi, allowing blood to flow to blood vessels affected by the thrombus. Such thrombolytic agents include streptokinase, urokinase, prourokin...